Reimagining Bell’s Palsy Care: Integrating Evidence-Based Medicine, Surgical Innovation, and Neurorehabilitative Advances

The most prevalent cause of acute unilateral lower motor neuron facial paralysis is Bell's palsy due to reactivation of herpes simplex virus type 1, which causes intraneural inflammation and edema in the narrow labyrinthine portion of the Fallopian canal. Recent evidence reiterates the use of early corticosteroid therapy as the gold-standard intervention by which full recovery can be achieved, with significant enhancement of complete recovery rates in cases where early antiviral therapy is used, but only in cases of severe muscular paralysis or suspected viral reactivation. Electrodiagnostic studies involving electroneuronography (ENoG) and electromyography (EMG) continue to play a central role in prognostication and surgical decision-making, with over 90% degeneration predicting poor spontaneous recovery as well as the small group who might benefit in terms of early facial nerve decompression through transmastoid or middle cranial fossa surgeries. In patients who have suffered irreversible paralysis, the late-stage reanimation procedures, such as nerve transfers, cross-facial nerve grafts, and free functional muscle transfer, can be of significant use in providing dynamic movement and facial symmetry. Neuromuscular retraining, biofeedback, photobiomodulation, and specific botulinum toxin therapy are also included in the rehabilitation modalities that contribute further to the improvement of functional outcomes and control of synkinesis. The latest technological developments, such as 3D photogrammetry, deep-learning-based facial movement quantification, and multi-omics profiling, make it possible to achieve individual diagnostic accuracy and treatment planning more and more. This study aims to enhance the perspective of adjunctive therapies, improve the application of surgical criteria, and develop predictive models that can lead to optimal patient care.